About 1,960,965 results (3,575 milliseconds)

WO2008049231A1 - Tissue targeted antigenic activation of the ...

https://patents.google.com/patent/WO2008049231A1/en
[0039] Figure 10 shows a survival curve for a cumulative series of stage 3B lung cancer patients who were treated with an oral antigen therapy, Respivax, ...

Blog post list

https://www.google.com/googleblogs/pdfs/google_public_data_march2010.pdf
cancer, ovarian cancer. Example searches: small cell lung cancer life expectancy, stage 3b lung cancer life expectancy, lung cancer survival rate, stage 4 ...

EP2598165A1 - Immunogenic anti-inflammatory compositions ...

https://patents.google.com/patent/EP2598165A1/en
[0070] Figure 3 shows a survival curve for a cumulative series of patients diagnosed with stage 3B or 4 lung cancer, illustrating the benefits of treatment with ...

WO2017202962A1 - Methods and pharmaceutical compositions for ...

https://patents.google.com/patent/WO2017202962A1/en
Lung cancer is associated with COPD in approximately 40-60% of the cases. COPD worsens the survival of patients with early-stage NSCLC (39) and emphysema is ...

WO2022198322A1 - Perioperative innate immune priming in cancer ...

https://patents.google.com/patent/WO2022198322A1
In accordance with the present invention, one may choose an influenza A subtype most commonly associated with lung infection to target immune dysregulation in ...

WO2018187228A1 - Serological biomarkers for early diagnosis of ...

https://patents.google.com/patent/WO2018187228A1/en
In some instances, a late stage lung cancer can be a stage III or stage IV lung cancer. ... one of claims 159-164, wherein the cancer is lung cancer. 166 ...

WO2018234879A1 - Il-1beta binding antibodies for use in treating ...

https://patents.google.com/patent/WO2018234879A1/en
In one embodiment, the patient has stage IIIB NSCLC. ... In one embodiment the patient with lung cancer receives canakinumab monthly or every three weeks.

US20210017606A1 - Marker Genes for Prostate Cancer ...

https://patents.google.com/patent/US20210017606A1/en
... cancer could eliminate the cancer and thus the life threat. In the ... JP2008521412A 2008-06-26 Lung cancer prognosis judging means. CN107709636A ...

CA3064363A1 - Non-small cell lung cancer biomarkers and uses ...

https://patents.google.com/patent/CA3064363A1/en
Stage IIIB, cancer cells are located on the opposite side of the chest from ... This demonstrates the clear need for diagnostic methods that can reliably detect ...

RU2723092C2 - Novel peptides and peptide combinations for use ...

https://patents.google.com/patent/RU2723092C2/en
Recent studies indicate that early stage survival rates for numb coccellular lung cancer are improved if chemotherapy is followed by surgery. Since the disease ...

US20090291434A1 - Gene expression markers for colorectal ...

https://patents.google.com/patent/US20090291434A1/en
Furthermore, the three-year survival rate for Stage III colon cancer patients treated with surgery alone is about 47% and it has not been established ...

WO2016075455A1 - Larp1 as cancer marker in serum or plasma ...

https://patents.google.com/patent/WO2016075455A1/no
... cancer therapy or drug can also be administered in combination with one ... Immunohistochemistry biomarkers predict survival in stage II/III gastric cancer ...

KR20160038889A - Novel immunotherapy against several tumors ...

https://patents.google.com/patent/KR20160038889A/en
Thus, overexpression of AKR1C is an indicator of poor prognosis and chemotherapy resistance in human non-small cell lung cancer (NSCLC) (Wang et al., 2007).

Researchers identify key regulator of blood stem cell development ...

https://news.google.com/__i/rss/rd/articles/CBMiPmh0dHBzOi8vd3d3LnNjaWVuY2VkYWlseS5jb20vcmVsZWFzZXMvMjAyMi8wMS8yMjAxMjgxNTM1NDMuaHRt0gEA?oc=5
Jan 28, 2022 ... 3 does in HSCs, and in other cell types where it appears, has been ... Lung Cancer · Brain Tumor · Plants & Animals · Biotechnology · Genetics ...

CA2801110A1 - Lung cancer biomarkers and uses thereof - Google ...

https://patents.google.com/patent/CA2801110A1/en
Stage IIIB, cancer ... [00123] Figure 7 is a flowchart for a method of indicating the likelihood that an individual has lung cancer in accordance with one ...

US20150268245A1 - In vitro method for the prognosis of ...

https://patents.google.com/patent/US20150268245A1/en
... prognosis of the outcome of cancers in patients undergoing cancers at an rearly stage. ... stage iii colorectal cancer. EP3752252A4 2018-02-12 2021-11-17 ...

EP3750558A1 - Novel peptides and combination of peptides for use ...

https://patents.google.com/patent/EP3750558A1/en
At presentation, 30-40% of cases of NSCLC are stage IV, and 60% of SCLC are stage IV. the 1-year relative survival for lung cancer has slightly increased ...

KR101916853B1 - Immunogenic anti-inflammatory compositions ...

https://patents.google.com/patent/KR101916853B1/en
Thus, according to some embodiments, patients with lung cancer 3B can be ... None of the 3B patients with lung cancer who were not treated with MRV survived ...

US8080650B2 - Pro104 antibody compositions and methods of use ...

https://patents.google.com/patent/US8080650B2/en
Stage III ovarian cancer involves tumor growth in one or both ovaries, with ... Radiation therapy can also be used to palliate (relieve) symptoms of lung cancer ...